| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Talditercept alfa | RO-7239361; BMS-986089; RG-6206; BHV-2000 | Phase 3 Clinical | Bristol-Myers Squibb Company | Muscular Atrophy, Spinal; Muscular Dystrophy, Duchenne; Neuromuscular Diseases; Obesity; Overweight | Details |
| Emugrobart | GYM-329; RG-6237; RG-70240; RO-7204239 | Phase 3 Clinical | Chugai Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2; Muscular Atrophy, Spinal; Muscular Dystrophy, Facioscapulohumeral; Obesity; Overweight | Details |
| Trevogrumab | REGN-1033; REGN1033; SAR-391786; GDF8 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Myositis, Inclusion Body; Obesity; Sarcopenia | Details |
| AAV1-FS344 | AAV1-Follistatin; AAV1-FS344 | Phase 2 Clinical | Nationwide Children'S Hospital | Becker muscular dystrophy; Muscular Dystrophy, Duchenne; Myositis, Inclusion Body | Details |
| EL-22 | EL-22 | Phase 1 Clinical | Obesity | Details | |
| IBIO-600 | IBIO-600 | Phase 1 Clinical | AstralBio Inc | Obesity; Overweight | Details |
| Rinvatercept | RKER-065; KER-065 | Phase 1 Clinical | Keros Therapeutics Inc | Neuromuscular Diseases; Obesity | Details |
| SRK-439 | SRK-439 | Phase 1 Clinical | Scholar Rock Inc | Heart Diseases; Obesity | Details |